Active, Recruiting

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

This is a Phase II/III trial across North America cooperative groups to study what kind of chemotherapy to recommend to low risk, Stage III colon cancer (T1-3, N1) patients based on the presence or absence of ctDNA after surgery for colon cancer.

ctDNA positive patients randomized to FOLFIRI (12 cycles) or surveillance. If MSI-H, receive nivolumab (12 cycles). If BRAF mutation is present, receive encorafenib, binimetinib, and cetuximab (12 cycles).